Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 12-Month High – Time to Buy?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares reached a new 52-week high on Monday . The stock traded as high as $131.40 and last traded at $131.30, with a volume of 1500320 shares trading hands. The stock had previously closed at $131.36.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Mizuho lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $140.00 to $132.00 in a research note on Monday, February 24th. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a research note on Wednesday, March 12th. They issued a “hold” rating on the stock. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their target price for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Ten equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Stock Down 0.1 %

The stock has a market cap of $13.96 billion, a price-to-earnings ratio of -150.89 and a beta of 0.69. The company has a 50 day simple moving average of $123.95 and a 200 day simple moving average of $95.70.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. As a group, analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Intra-Cellular Therapies

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Accredited Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies in the 4th quarter worth about $28,000. True Wealth Design LLC bought a new position in shares of Intra-Cellular Therapies during the 3rd quarter valued at approximately $32,000. GAMMA Investing LLC grew its position in shares of Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 240 shares during the period. Venturi Wealth Management LLC bought a new position in shares of Intra-Cellular Therapies during the 4th quarter valued at approximately $96,000. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Intra-Cellular Therapies during the 3rd quarter valued at approximately $97,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.